• Citer

Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

par Van Praet, Charles;Filleul, Bertrand;Schallier, Denis;Machiels, Jean Pascal;Schrijvers, Dirk;Everaert, Els;D'Hondt, Lionel;Werbrouck, Patrick;Vermeij, Joanna;Mebis, Jeroen;Clausse, Marylene;Rottey, Sylvie;Rasschaert, Marika;Van Erps, Joanna;Verheezen, Jolanda;Van Haverbeke, Jan;Goeminne, Jean Charles;Lumen, Nicolaas;Van Hende, Fransien;Pelgrims, Gino;Demey, Wim;Van Aelst, Filip;Wynendaele, Wim;Gil, Thierry ;Schatteman, Peter
Référence Clinical Genitourinary Cancer, 15, 4, page (502-508)
Publication Publié, 2017-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Micro-Abstract Individual patients' survival varies greatly in metastatic castration-resistant prostate cancer. Retrospective analysis of 368 patients treated with docetaxel and starting abiraterone acetate revealed 5 adverse prognostic factors: hemoglobin < 12 g/dL, > 10 metastases, ECOG performance status ≥ 2, radiographic progression, and time since diagnosis < 90 months. A prognostic model stratifies patients into 3 groups with different estimated survival, which can aid in patient counseling.